BeStock  
Stocks › Biotechnology › VKTX

Viking Therapeutics VKTX

US equityMarket cap rank #2332Biotechnology
$29.28 −$0.66 (-2.20%)
Pre-market · Oct 6, 4:20 am ET · After hours $29.33 +0.17%
Open$30.14
Prev close$29.94
Day range$28.71 – $30.18
Volume6.28M
Market cap$3.68B
P/E (TTM)–
Dividend yield–

Fundamentals

Latest reported quarter: ANNUAL, ended Dec 2025

Revenue$0.00
Operating profit-$393.34M-160.6% YoY
Net profit-$359.64M-227.1% YoY
Diluted EPS-$3.19-215.8% YoY

Annual revenue

$0.0FY20$0.0FY21$0.0FY22$0.0FY23$0.0FY24$0.0FY25

Profitability & balance sheet

Liabilities / assets21.8%
Cash & investments$501.66M
Total debt$3.93M
Net cash (debt)$497.74M

Balance sheet

Line item 2026 Q2 2026 Q1 2025 Q4 2025 Q3 2025 Q2
Total Assets $521.90M $608.24M $715.73M $739.42M $827.85M
Total Current Liabilities $109.66M $106.33M $76.67M $26.07M $31.98M
Total Liabilities $113.58M $106.33M $76.67M $26.39M $32.39M
Other Non-Current Assets $211,000.00 – – – –
Non-Current Prepaid Assets $113,000.00 $33,000.00 $46,000.00 $46,000.00 $46,000.00
-Gross PPE $4.01M $0.00 $85,000.00 $666,000.00 $780,000.00
Net PPE $4.01M $0.00 $85,000.00 $666,000.00 $780,000.00
Total Non-Current Assets $4.33M $33,000.00 $131,000.00 $712,000.00 $834,000.00
Other Current Assets $941,000.00 $1.22M $1.81M $2.24M $2.82M
Prepaid Assets $14.96M $4.02M $8.05M $21.89M $16.48M
-Short Term Investments $375.91M $484.85M $539.93M $614.19M $773.84M
-Cash and Cash Equivalents $125.75M $118.12M $165.81M $100.38M $33.88M
Cash and Cash Equivalents & Short-Term Investments $501.66M $602.96M $705.74M $714.57M $807.72M
Gains/Losses Not Affecting Retained Earnings -$1.15M -$856,000.00 $378,000.00 $374,000.00 -$166,000.00
Payables $69.01M $67.18M $53.25M $4.41M $5.49M
-Accounts Payable $69.01M $67.18M $53.25M $4.41M $5.49M
Total Current Assets $517.56M $608.21M $715.60M $738.70M $827.02M
Retained Earnings -$1.13B -$1.01B -$847.55M -$689.88M -$599.10M
Additional Paid-In Capital $1.54B $1.51B $1.49B $1.40B $1.39B
-Preferred Stock $0.00 $0.00 $0.00 $0.00 $0.00
-Common Stock $1,000.00 $1,000.00 $1,000.00 $1,000.00 $1,000.00
Capital Stock $1,000.00 $1,000.00 $1,000.00 $1,000.00 $1,000.00
Stockholders' Equity $408.32M $501.92M $639.06M $713.03M $795.46M
Total Equity $408.32M $501.92M $639.06M $713.03M $795.46M
Current Accrued Expenses $40.48M $39.14M $23.28M $21.22M $26.02M
Short-Term Debt and Capital Lease Obligation $161,000.00 – $137,000.00 $437,000.00 $468,000.00
-Current Capital Lease Obligation $161,000.00 $0.00 $137,000.00 $437,000.00 $468,000.00
Total Non-Current Liabilities $3.93M $0.00 $0.00 $318,000.00 $410,000.00
Long Term Debt and Capital Lease Obligation $3.93M – $0.00 $318,000.00 $410,000.00
-Long Term Capital Lease Obligation $3.93M – $0.00 $318,000.00 $410,000.00
Less: Treasury Stock – $0.00 $0.00 $0.00 $0.00
Non-Current Deferred Assets – – $0.00 $0.00 $8,000.00

Income statement

Line item 2025 ANNUAL 2024 ANNUAL 2023 ANNUAL 2022 ANNUAL 2021 ANNUAL
Net Profit -$359.64M -$109.96M -$85.90M -$68.87M -$54.99M
Profit from Continuing Operations -$359.64M -$109.96M -$85.90M -$68.87M -$54.99M
Net Income to Parent Company -$359.64M -$109.96M -$85.90M -$68.87M -$54.99M
Net Income to Common Stockholders -$359.64M -$109.96M -$85.90M -$68.87M -$54.99M
Basic EPS -$3.19 -$1.01 -$0.91 -$0.90 -$0.71
Pretax Profit -$359.64M -$109.96M -$85.90M -$68.87M -$54.99M
Gain on Sale of Security $55,000.00 $112,000.00 – -$42,000.00 $7,000.00
Other Income (Expense) $55,000.00 $112,000.00 – -$42,000.00 $7,000.00
Total Revenue as Reported $0.00 $0.00 $0.00 $0.00 $0.00
Total Operating Revenue $0.00 $0.00 $0.00 $0.00 $0.00
Operating Expense $393.34M $150.92M $100.83M $70.36M $55.68M
Selling and Admin Expenses $48.39M $49.28M $37.02M $16.12M $10.70M
-General & Admin Expense $48.39M $49.28M $37.02M $16.12M $10.70M
Research & Development $344.96M $101.64M $63.81M $54.23M $44.98M
Operating Profit -$393.34M -$150.92M -$100.83M -$70.36M -$55.68M
Net Non-Operating Interest Income (Expense) $33.65M $40.85M $14.93M $1.53M $685,000.00
Non-Operating Interest Income $33.70M $40.94M $15.02M $1.59M $703,000.00
Total Other Finance Costs $56,000.00 $94,000.00 $88,000.00 $59,000.00 $18,000.00
Diluted EPS -$3.19 -$1.01 -$0.91 -$0.90 -$0.71

Discussion

No comments yet — be the first to weigh in on VKTX.

Leave a comment

Scroll to Top